Denis RD, Stabile A, Stamen R, Stamm S, Stanecka E, Stanek RW, Stanescu C, Stanescu-Bellu M, Stanitzki MM, Stapnes S, Starchenko EA, Stark GH, Stark J, Staroba P, Starovoitov P, Stärz S, Staszewski R, Steinberg P, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stewart GA, Stillings JA, Stockton MC, Stoebe M, Stoicea G, Stolte P, Stonjek S, Stradling AR, Straessner A, Stramaglia ME, Strandberg J, Strandberg S, Strandlie A, Strauss M, Strizenec P, Ströhmer R, Strom DM, Stroynowski R, Strubig A, Stucci SA, Stugu B, Styles NA, Su D, Su J, Suchek S, Sugaya Y, Suk M, Sulin VV, Sultansoy S, Sumida T, Sun S, Sun X, Sundermann JE, Suruliz K, Suster CJE, Sutton MR, Suzuki S, Svatos M, Swiatlowski M, Swift SP, Sykora I, Sykora T, Ta D, Taccini C, Tackmann K, Taenzer J, Taffard A, Tafirout R, Taiblum N, Takai H, Takashima R, Takeshita T, Takubo Y, Talby M, Talyshev AA, Tan KG, Tanaka J, Tanaka M, Tanaka R, Tanaka S, Tanioka R, Tannenwald BB, Tapia Araya S, Tapprogge S, Tarem S, Tartarelli GF, Tas P, Tasevsky M, Tashiro T, Tassi E, Tavares Delgado A, Tayalati Y, Taylor AC, Taylor GN, Taylor PTE, Taylor W, Teischinger FA, Teixeira-Dias P, Temming KK, Temple D, Ten Kate H, Teng PK, Teoh JJ, Tepel F, Terada S, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Theveneaux-Pelzer T, Thomas JP, Thomas-Wilsker J, Thompson PD, Thompson AS, Thomsen LA, Thomson E, Tibbetts MJ, Ticse Torres RE, Tikhomirov VO, Tikhonov YA, Timoshenko S, Tipton P, Tisserant S, Todome K, Todorov T, Todorova-Nova S, Tojo J, Tokár S, Tokushuku K, Tolley E, Tomlinson L, Tomoto M, Tompkins L, Toms K, Tong B, Tornambe P, Torrence E, Torres H, Torró Pastor E, Toth J, Touchard F, Tovey DR, Trefzger T, Tricoli A, Trigger IM, Trincaz-Duvoid S, Tripiana MF, Trischuk W, Trocmé B, Trofymov A, Troncon C, Trottier-McDonald M, Trovatelli M, Truong L, Trzebinski M, Trzupek A, Tseng JL, Tsiareshka PV, Tsipolitis G, Tsirintanis N, Tsiskaridze S, Tsiskaridze V, Tskhadadze EG, Tsui KM, Tsukerman II, Tsulaia V, Tsuno S, Tsybychev D, Tu Y, Tudorache A, Tudorache V, Tulbure TT, Tuna AN, Tupputi SA, Turchikhin S, Turgeman D, Turk Cakir I, Turra R, Tuts PM, Ucchielli G, Ueda I, Ughetto M, Ukegawa F, Unal G, Undrus A, Unel G, Ungaro FC, Unno Y, Unverdorben C, Urban J, Urquijo P, Urrejola P, Usai G, Usui J, Vacavant L, Vacek V, Vachon B, Valderanis C, Valdes Santurio E, Valencic N, Valentinetti S, Valero A, Valery L, Valkar S, Valls Ferrer JA, Van Den Wollenberg W, Van Der Deijl PC, van der Graaf H, van Eldik N, van Gemmeren P, Van Nieuwkoop J, van Vulpen I, van Woerden MC, Vanadia M, Vandelli W, Vanguri R, Vaniachine A, Vankov P, Vardanyan G, Vari R, Varnes EW, Varol T, Varouchas D, Vartapetian A, Varvell KE, Vasquez JG, Vasquez GA, Vazeille F, Vazquez Schroeder T, Veatch J, Veeraraghavan V, Veloce LM, Veloso F, Veneziano S, Ventura A, Venturi M, Venturi N, Venturini A, Vercesi V, Verducci M, Verkerke W, Vermeulen JC, Vest A, Vetterli MC, Viazlo O, Vichou I, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Viel S, Vigani L, Villa M, Villaplana Perez M, Vilucchi E, Vincter MG, Vinogradov VB, Vittori C, Vivarelli I, Vlachos S, Vlasak M, Vogel M, Vokac P, Volpi G, Volpi M, von der Schmitt H, von Toerne E, Vorobel V, Vorobev K, Vos M, Voss R, Vossebeld JH, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vuillermet R, Vukotic I, Wagner P, Wagner W, Wahlberg H, Wahrmund S, Wakabayashi J, Walder J, Walker R, Walkowiak W, Wallangen V, Wang C, Wang C, Wang F, Wang H, Wang H, Wang J, Wang J, Wang K, Wang R, Wang SM, Wang T, Wang W, Wanotayaroj C, Warburton A, Ward CP, Wardrope DR, Washbrook A, Watkins PM, Watson AT, Watson MF, Watts G, Watts S, Waugh BM, Webb S, Weber MS, Weber SW, Weber SA, Webster JS, Weidberg AR, Weinert B, Weingarten J, Weiser C, Weits H, Wells PS, Wenaus T, Wengler T, Wenig S, Wermes N, Werner MD, Werner P, Wessels M, Wetter J, Whalen K, Whallon NL, Wharton AM, White A, White MJ, White R, Whiteson D, Wickens FJ, Wiedenmann W, Wielers M, Wiglesworth C, Wiik-Fuchs LAM, Wildauer A, Wilk F, Wilkens HG, Williams HH, Williams S, Willis C, Willocq S, Wilson JA, Wingerter-Seez I, Winklmeier F, Winston OJ, Winter BT, Wittgen M, Wolf TMH, Wolff R, Wolter MW, Wolters H, Worm SD, Wosiek BK, Wotschack J, Woudstra MJ, Wozniak KW, Wu M, Wu M, Wu SL, Wu X, Wu Y, Wyatt TR, Wynne BM, Xella S, Xi Z, Xu D, Xu L, Yabsley B, Yacoob S, Yamaguchi D, Yamaguchi Y, Yamamoto A, Yamamoto S, Yamanaka T, Yamauchi K, Yamazaki Y, Yan Z, Yang H, Yang H, Yang Y, Yang Z, Yao WM, Yap YC, Yasu Y, Yatsenko E, Yau Wong KH, Ye J, Ye S, Yeletskikh I, Yildirim E, Yorita K, Yoshida R, Yoshihara K, Young C, Young CJS, Youssef S, Yu DR, Yu J, Yu JM, Yu J, Yuan L, Yuen SPY, Yusuff I, Zabinski B, Zaidan R, Zaitsev AM, Zakharchuk N, Zalieckas J, Zaman A, Zambito S, Zanello L, Zanzi D, Zeitnitz C, Zeman M, Zemla A, Zeng JC, Zeng Q, Zenin O, Ženiš T, Zerwas D, Zhang D, Zhang F, Zhang G, Zhang H, Zhang J, Zhang L, Zhang L, Zhang M, Zhang R, Zhang R, Zhang X, Zhang Z, Zhao X, Zhao Y, Zhao Z, Zhemchugov A, Zhong J, Zhou B, Zhou C, Zhou L, Zhou L, Zhou M, Zhou N, Zhu CG, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhukov K, Zibell A, Zieminska D, Zimine NI, Zimmermann C, Zimmermann S, Zinonos Z, Zinser M, Ziolkowski M, Živković L, Zobernig G, Zoccoli A, zur Nedden M, Zwalinski L. Measurement of the prompt J/[Formula: see text] pair production cross-section in pp collisions at [Formula: see text] TeV with the ATLAS detector

The production of two prompt [Formula: see text] mesons, each with transverse momenta [Formula: see text] GeV and rapidity [Formula: see text], is studied using a sample of proton-proton collisions at [Formula: see text] TeV, corresponding to an integrated luminosity of 11.4 fb[Formula: see text] collected in 2012 with the ATLAS detector at the LHC. The differential cross-section, assuming unpolarised [Formula: see text] production, is measured as a function of the transverse momentum of the lower-[Formula: see text] [Formula: see text] meson, di-[Formula: see text] [Formula: see text] and mass, the difference in rapidity between the two [Formula: see text] mesons, and the azimuthal angle between the two [Formula: see text] mesons. The fraction of prompt pair events due to double parton scattering is determined by studying kinematic correlations between the two [Formula: see text] mesons. The total and double parton scattering cross-sections are compared with predictions. The effective cross-section of double parton scattering is measured to be [Formula: see text] mb.

Heparin-binding Hemagglutinin of Mycobacterium tuberculosis Is an Inhibitor of Autophagy

Airway epithelial cell is often the initial site of attack by pathogens, and cell death is commonly caused by internalization of Mycobacterium tuberculosis (Mtb). However, the mechanism of interaction between epithelial cells and Mtb is not well understood. In this study, we investigated the role of the heparin-binding hemagglutinin (HBHA) protein of Mtb in the function of epithelial cells. In particular, the autophagy of A549 cells was determined based on microtubule-associated protein 1 light chain 3 alpha (LC3) activity. Autophagosome formation was detected by Monodansylcadaverine (MDC) staining and immune fluorescence staining of LC3. Autophagy could be significantly suppressed by HBHA protein. In addition, the LDH assay results showed that HBHA treatment could induce death on A549 cells. To explore the form of cell death, we detected the activity of caspase-3 and LDH release of A549 cells in the presence or absence of caspase inhibitor Z-VAD-FMK. Results demonstrated that HBHA treatment could induce apoptosis of A549 cells. To further confirm these results, we constructed the recombinant Mycobacterium smegmatis (MS) expressing HBHA (rMS-HBHA) and explored the influence of rMS-HBHA on the function of A549 cells. rMS-HBHA infection significantly inhibited LC3 expression and the maturation of autophagosomes in A549 cells. Subsequently, we infected A549 cells with MS and detected the viability of intracellular MS by CFU counts. rMS-HBHA showed higher survival and replication capacity in A549 cells than those of the wild-type MS. Finally, infection of A549 cells with rMS-HBHA caused further apoptosis. These findings suggested that rMS-HBHA could inhibit autophagy, promote its survival and replication within A549 cells, and subsequently induce apoptosis on infected cells to facilitate infection.

See-through near-eye displays enabling vision correction

We propose a see-through near-eye display, which is dedicated to the visually impaired users who suffer from refractive anomalies. Our solution is characterized by a pair of corrective lenses coated with multiplexed volume holograms. Its key performance including diffraction efficiency, field of view, modulation transfer function, and distortion has been studied.

Search for lepton-flavour-violating decays of the Higgs and Z bosons with the ATLAS detector

Direct searches for lepton flavour violation in decays of the Higgs and Z bosons with the ATLAS detector at the LHC are presented. The following three decays are considered: [Formula: see text], [Formula: see text], and [Formula: see text]. The searches are based on the data sample of proton-proton collisions collected by the ATLAS detector corresponding to an integrated luminosity of 20.3 [Formula: see text] at a centre-of-mass energy of [Formula: see text] TeV. No significant excess is observed, and upper limits on the lepton-flavour-violating branching ratios are set at the 95[Formula: see text] confidence level: Br[Formula: see text], Br[Formula: see text], and Br[Formula: see text].

Development and Evaluation of Up-Converting Phosphor Technology-Based Lateral Flow Assay for Quantitative Detection of NT-proBNP in Blood

A newly assay, up-converting phosphor technology-based lateral flow (UPT-LF) assay, was developed for rapid and quantitative detection of N-terminal fragment of B-type natriuretic peptide precursor (NT-proBNP), one of the most important serum molecular maker of heat failure, in plasma samples as a point of care testing (POCT) method for diagnosis of acute heart failure. Human plasma from 197 patients with acute heart failure and 200 healthy controls was assessed using the UPT-LF assay, in a comparison with a Roche Elecsys assay. The limit of detection of the UPT-LF assay, with a coefficient of variation (CV) of less than 15%, was 116 ng/L, which is lower than the clinical diagnosis cutoff (150 ng/mL). The linear range was 50-35,000 ng/L. The CVs were less than 10% for both UPT-LF and Roche Elecsys assays for plasma samples under different storages, demonstrating the good stability and reproducibility. There are certain linear correlations between the results of UPT-LF and Roche Elecsys assay for EDTA-K2 and heparin-anticoagulated plasma, as well as for serum samples. For UPT-LF assay, there is a significant correlation between the values derived from analysis of EDTA-K2 and heparin-anticoagulated plasma samples (R = 0.995). No statistically significant difference was found between serum and plasma samples for UPT-LF assay. Our results demonstrate that NT-proBNP levels in healthy adults are elevated with age and had a relationship with sex, and with the age increase the NT-proBNP levels of females are significantly higher than those of males (p<0.01). The UPT-LF assay has a high reproducibility, stability, sensitivity, specificity, and is consistent with Roche Elecsys assay, and therefore it could be used as a POCT method for the quantitative detection of NT-proBNP in blood for clinical diagnosis and research of acute heart failure.

Enhancing As(V) adsorption and passivation using biologically formed nano-sized FeS coatings on limestone: Implications for acid mine drainage treatment and neutralization

The iron-reducing bacterium Acidiphilium cryputum JF-5 and a sulfate reducing bacterium (SRB) collected and purified from the mine drainage of a copper mine in the northwest of Sichuan Province, China, were used to biologically synthesize nano-sized FeS-coated limestone to remove As(V) from solution. The adsorption efficiency of As(V) is improved from 6.64 μg/g with limestone alone to 187 μg/g with the FeS coated limestone in both batch and column experiments. The hydraulic conductivity of the columns are also improved by the presence of the nano-sized FeS coatings, but the solution neutralization performance of the limestone can be reduced by passivation by gypsum and Fe(III) precipitates. Calculations for FeS-coated limestone dissolution experiments show that the process can be described as n_Ca.sol = At^1/2 - n_Ca,gyp. The results suggest that FeS-coated limestone may be an effective medium for remediating As(V)-bearing solutions such as acid mine drainage in systems such as Permeable Reactive Barriers.

A minicircuitry comprised of microRNA-9 and SIRT1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia

OBJECTIVE

The AML1-ETO fusion protein (AE) resulting from the t(8;21) translocation is highly related to the pathogenesis and development of leukemia. microRNA-9 (miR-9) acts as a tumor suppressor gene in AE-positive acute myeloid leukemia (AML). Silent mating type information regulation 2 homolog-1 (SIRT1) is overexpressed in most cancer cells by increasing proliferation as a tumorigenic gene. The present study was performed to investigate the underlying interaction between miR-9 and SIRT1 in AE-positive AML.

PATIENTS AND METHODS

Expression of miR-9 and SIRT1 in AE-positive AML patients, healthy donors and AML cell lines were detected by qPCR. Relevance between miR-9 and SIRT1 was assessed by plasmid transfection, Western blot and correlation analysis. Luciferase assay was used to confirm the target gene of miR-9. Knockdown of SIRT1 in different cell lines was achieved by shRNA transfection and CCK-8 assay was used to investigate the effects on cell proliferation.

RESULTS

The miR-9 expression was lower in AE-positive cell lines compared to that in other AE-negative AML cell lines, while expression of SIRT1 was higher in AE-positive cell lines. Expression of miR-9 was also downregulated in adult primary t(8;21) AML patients compared to healthy donors. The over-expression of miR-9 decreased luciferase activity of wild-type SIRT1, which was recovered after transfection with mutant SIRT1. The miR-9 directly targets SIRT1 by binding to its 3'-untranslated region and reducing its protein levels. Importantly, miR-9 and SIRT1 mRNA levels were inversely correlated in AE-positive AML cell lines and t(8;21) AML primary leukemia cells. Knockdown of SIRT1 levels using shSIRT1 inhibited cell proliferation in AE-positive AML cell lines.

CONCLUSIONS

SIRT1 is the target gene of miR-9 and the signaling pathway connecting miR-9 and SIRT1 is a therapeutic target for t(8;21) AML.

Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC)

279

Background: Tarextumab (TRXT), fully human IgG2 antibody inhibits signaling of Notch2/ 3 receptors. Tumor regression seen in Notch3 (N3) expressing pt-derived pancreatic cancer xenografts when TRXT combined with Nab-P+Gem. Phase 2, randomized, placebo-controlled trial conducted to evaluate efficacy, safety of combination in mPC. Methods: Pts randomized 1:1 to TRXT or placebo (PL). TRXT given IV at 15 mg/kg q 2wks (D 1, 15), nab-P 125 mg/m2, GEM 1000mg/m2 on D1, 8, 15 q 28 days. Tissue for N3 gene expression determination was required. Primary endpoints: overall survival (OS) in all and in 3 subgroups determined by Notch 3 gene expression. Secondary: safety, progression-free survival (PFS) and overall response rate (ORR). Results: N = 177 pts randomized. Performance status (0 or 1), CA19-9 stratum (0 – ULN, > ULN – 59ULN, ≥ 59ULN) balanced. Clinical trial information: NCT01647828. .  Conclusions: Addition of TRXT to Nab-P+Gem did not improve OS in 1st line mPC. A potential detrimental effect on PFS and ORR was seen in subjects with N3 < 25%ile.[Table: see text]

Hierarchical CoNi-Sulfide Nanosheet Arrays Derived from Layered Double Hydroxides toward Efficient Hydrazine Electrooxidation

A hierarchical CoNi-sulfide nanosheet array is fabricated via an in situ reduction of CoNi-layered double hydroxide (LDH) nanosheets, then a vulcanization process. The material inherits the morphology of the LDH precursor, consisting of well-distributed CoNi-alloy@CoNi-sulfide nanoparticles with a core-shell structure, and demonstrates promising performance toward hydrazine electrooxidation.

Aquatic photolysis of β2-agonist salbutamol: kinetics and mechanism studies

Salbutamol (SAL) has been widely used as medicine both in treating asthma and in animal primary production; an increasing number of reports have detected SAL in natural waters. The photolysis kinetic and pathway of SAL in aquatic system were studied, as well as the effect of several natural water constituents, such as nitrate, dissolved oxygen (DO) and ferric ions. According to our research, the direct photolysis of SAL followed pseudo-first-order reaction kinetics. Alkaline condition could promote the degradation of SAL; the increase of solution pH would simultaneously increase the fraction of the deprotonated forms of SAL (including the deprotonated and zwitterionic species), which were easier to be excited, and result in the bathochromic shift of the UV-Vis spectrum and, finally, accelerate the degradation rate of SAL. The presence of nitrate could enhance the removal rate of SAL via generation hydroxyl radical (·OH) under irradiation. In addition, the absence of oxygen in the reaction solution could decrease the photolysis. Moreover, Fe(III) was able to chelate with SAL to form an octahedral complex, which was photochemically reactive. The octahedral complex could generate ·OH to oxidize SAL itself in turn. The pathways of SAL photolysis were also investigated by means of the solid phase extraction (SPE)-LC-MS method. The major pathways of SAL photodegradation included oxidation and side-chain cleavage.

Upconversion Nanocrystals Mediated Lateral-Flow Nanoplatform for in Vitro Detection

Upconversion phosphors (UCPs) that are free from interference from biological sample autofluorescence have attracted attention for in vivo and in vitro bioapplications. However, UCPs need to be water-dispersible, nanosized, and highly luminous to realize broad applications. Therefore, the aim of this research is to develop UCPs that meet these comprehensive criteria for in vitro diagnosis. To combine nano size with high luminous intensity, β-NaYF₄:Yb³⁺,Er³⁺ upconversion nanocrystals (UCNPs) codoped with Li⁺ and K⁺ are prepared that display high upconversion intensities as well as small size. The strongest green and red emissions of the Na_0.9Li_0.07K_0.03YF₄:Yb³⁺,Er³⁺ nanocrystals are increased by 7 and 10 times, respectively, compared with those of the undoped NaYF₄:Yb³⁺,Er³⁺ nanocrystals. A mild sol-gel surface modification method is used to produce water-phase dispersions and allow covalent biomolecule conjugation. The bioactivated UCNPs are used as a bioreporter and integrated with a classical lateral flow assay to establish an assay to accomplish simultaneous dual-target detection of Yersinia pestis and Burkholderia pseudomallei. The assay achieves a sensitivity of 10³ CFU/test without cross-interference between two targets. The research provides a way to produce UCNPs with comprehensive properties for use as excellent optical reporters in in vivo and in vitro bioapplications.

Visible-Light-Mediated Two-Fold Unsymmetrical C(sp3 )-H Functionalization and Double C-F Substitution

A visible-light-mediated [3+3] annulation of tertiary amines with α-trifluoromethyl alkenes was developed. The reaction offers a direct route to fluorinated tetrahydropyridines and azabicyclo[3.m.1] frameworks under very mild conditions. This protocol presents a rare example of dual sp³ C-H functionalization of tertiary amines with the formation of two different C-C bonds (one sp³ -sp³ bond, one sp² -sp³ bond). Moreover, two consecutive C-F substitutions in a trifluoromethyl group were achieved in one pot using visible light photoredox catalysis, which enables an unprecedented ring construction.

Takayasu's arteritis presenting with common carotid artery dissection: A rare case report

Takayasu's arteritis (TA) is a rare, idiopathic, chronic inflammatory disease associated with cell-mediated inflammation and involving predominantly the aorta and its primary branches. TA results in stenosis, occlusion or aneurysmal degeneration of large arteries pathologically. However, the incidence of dissection in arteries is low. As one of the primary causes of aortic dissection-associated ischemic stroke in young adults, only a limited number of TA cases presenting with aortic dissection have been published to date. In the present study, a case of common carotid artery dissection in a young patient with TA, without evident clinical manifestations, is presented. This is a rare clinical phenomenon, but may be a risk factor of acute cerebrovascular events. Clinical examination and satisfactory imaging are crucial for the correct diagnosis and management of patients with TA with dissection in arteries, and great attention is required in order to prevent the occurrence of cerebrovascular ischemia.

Panagiotopoulou E, Pandini CE, Panduro Vazquez JG, Pani P, Panitkin S, Pantea D, Paolozzi L, Papadopoulou TD, Papageorgiou K, Paramonov A, Paredes Hernandez D, Parker AJ, Parker MA, Parker KA, Parodi F, Parsons JA, Parzefall U, Pascuzzi VR, Pasqualucci E, Passaggio S, Pastore F, Pásztor G, Pataraia S, Pater JR, Pauly T, Pearce J, Pearson B, Pedersen LE, Pedersen M, Lopez SP, Pedro R, Peleganchuk SV, Pelikan D, Penc O, Peng C, Peng H, Penwell J, Peralva BS, Perego MM, Perepelitsa DV, Perez Codina E, Perini L, Pernegger H, Perrella S, Peschke R, Peshekhonov VD, Peters K, Peters RFY, Petersen BA, Petersen TC, Petit E, Petridis A, Petridou C, Petroff P, Petrolo E, Petrov M, Petrucci F, Pettersson NE, Peyaud A, Pezoa R, Phillips PW, Piacquadio G, Pianori E, Picazio A, Piccaro E, Piccinini M, Pickering MA, Piegaia R, Pilcher JE, Pilkington AD, Pin AWJ, Pinamonti M, Pinfold JL, Pingel A, Pires S, Pirumov H, Pitt M, Plazak L, Pleier MA, Pleskot V, Plotnikova E, Plucinski P, Pluth D, Poettgen R, Poggioli L, Pohl D, Polesello G, Poley A, Policicchio A, Polifka R, Polini A, Pollard CS, Polychronakos V, Pommès K, Pontecorvo L, Pope BG, Popeneciu GA, Popovic DS, Poppleton A, Pospisil S, Potamianos K, Potrap IN, Potter CJ, Potter CT, Poulard G, Poveda J, Pozdnyakov V, Pozo Astigarraga ME, Pralavorio P, Pranko A, Prell S, Price D, Price LE, Primavera M, Prince S, Proissl M, Prokofiev K, Prokoshin F, Protopopescu S, Proudfoot J, Przybycien M, Puddu D, Purohit M, Puzo P, Qian J, Qin G, Qin Y, Quadt A, Quayle WB, Queitsch-Maitland M, Quilty D, Raddum S, Radeka V, Radescu V, Radhakrishnan SK, Radloff P, Rados P, Ragusa F, Rahal G, Raine JA, Rajagopalan S, Rammensee M, Rangel-Smith C, Ratti MG, Rauscher F, Rave S, Ravenscroft T, Ravinovich I, Raymond M, Read AL, Readioff NP, Reale M, Rebuzzi DM, Redelbach A, Redlinger G, Reece R, Reeves K, Rehnisch L, Reichert J, Reisin H, Rembser C, Ren H, Rescigno M, Resconi S, Rezanova OL, Reznicek P, Rezvani R, Richter R, Richter S, Richter-Was E, Ricken O, Ridel M, Rieck P, Riegel CJ, Rieger J, Rifki O, Rijssenbeek M, Rimoldi A, Rimoldi M, Rinaldi L, Ristić B, Ritsch E, Riu I, Rizatdinova F, Rizvi E, Rizzi C, Robertson SH, Robichaud-Veronneau A, Robinson D, Robinson JEM, Robson A, Roda C, Rodina Y, Rodriguez Perez A, Rodriguez Rodriguez D, Roe S, Rogan CS, Røhne O, Romaniouk A, Romano M, Romano Saez SM, Romero Adam E, Rompotis N, Ronzani M, Roos L, Ros E, Rosati S, Rosbach K, Rose P, Rosenthal O, Rosien NA, Rossetti V, Rossi E, Rossi LP, Rosten JHN, Rosten R, Rotaru M, Roth I, Rothberg J, Rousseau D, Royon CR, Rozanov A, Rozen Y, Ruan X, Rubbo F, Rudolph MS, Rühr F, Ruiz-Martinez A, Rurikova Z, Rusakovich NA, Ruschke A, Russell HL, Rutherfoord JP, Ruthmann N, Ryabov YF, Rybar M, Rybkin G, Ryu S, Ryzhov A, Rzehorz GF, Saavedra AF, Sabato G, Sacerdoti S, Sadrozinski HFW, Sadykov R, Safai Tehrani F, Saha P, Sahinsoy M, Saimpert M, Saito T, Sakamoto H, Sakurai Y, Salamanna G, Salamon A, Loyola JES, Salek D, De Bruin PHS, Salihagic D, Salnikov A, Salt J, Salvatore D, Salvatore F, Salvucci A, Salzburger A, Sammel D, Sampsonidis D, Sanchez A, Sánchez J, Sanchez Martinez V, Sandaker H, Sandbach RL, Sander HG, Sandhoff M, Sandoval C, Sandstroem R, Sankey DPC, Sannino M, Sansoni A, Santoni C, Santonico R, Santos H, Santoyo Castillo I, Sapp K, Sapronov A, Saraiva JG, Sarrazin B, Sasaki O, Sasaki Y, Sato K, Sauvage G, Sauvan E, Savage G, Savard P, Sawyer C, Sawyer L, Saxon J, Sbarra C, Sbrizzi A, Scanlon T, Scannicchio DA, Scarcella M, Scarfone V, Schaarschmidt J, Schacht P, Schachtner BM, Schaefer D, Schaefer R, Schaeffer J, Schaepe S, Schaetzel S, Schäfer U, Schaffer AC, Schaile D, Schamberger RD, Scharf V, Schegelsky VA, Scheirich D, Schernau M, Schiavi C, Schier S, Schillo C, Schioppa M, Schlenker S, Schmidt-Sommerfeld KR, Schmieden K, Schmitt C, Schmitt S, Schmitz S, Schneider B, Schnoor U, Schoeffel L, Schoening A, Schoenrock BD, Schopf E, Schott M, Schovancova J, Schramm S, Schreyer M, Schuh N, Schulte A, Schultens MJ, Schultz-Coulon HC, Schulz H, Schumacher M, Schumm BA, Schune P, Schwartzman A, Schwarz TA, Schwegler P, Schweiger H, Schwemling P, Schwienhorst R, Schwindling J, Schwindt T, Sciolla G, Scuri F, Scutti F, Searcy J, Seema P, Seidel SC, Seiden A, Seifert F, Seixas JM, Sekhniaidze G, Sekhon K, Sekula SJ, Seliverstov DM, Semprini-Cesari N, Serfon C, Serin L, Serkin L, Sessa M, Seuster R, Severini H, Sfiligoj T, Sforza F, Sfyrla A, Shabalina E, Shaikh NW, Shan LY, Shang R, Shank JT, Shapiro M, Shatalov PB, Shaw K, Shaw SM, Shcherbakova A, Shehu CY, Sherwood P, Shi L, Shimizu S, Shimmin CO, Shimojima M, Shiyakova M, Shmeleva A, Shoaleh Saadi D, Shochet MJ, Shojaii S, Shrestha S, Shulga E, Shupe MA, Sicho P, Sickles AM, Sidebo PE, Sidiropoulou O, Sidorov D, Sidoti A, Siegert F, Sijacki D, Silva J, Silverstein SB, Simak V, Simard O, Simic L, Simion S, Simioni E, Simmons B, Simon D, Simon M, Sinervo P, Sinev NB, Sioli M, Siragusa G, Sivoklokov SY, Sjölin J, Skinner MB, Skottowe HP, Skubic P, Slater M, Slavicek T, Slawinska M, Sliwa K, Slovak R, Smakhtin V, Smart BH, Smestad L, Smiesko J, Smirnov SY, Smirnov Y, Smirnova LN, Smirnova O, Smith MNK, Smith RW, Smizanska M, Smolek K, Snesarev AA, Snyder S, Sobie R, Socher F, Soffer A, Soh DA, Sokhrannyi G, Sanchez CAS, Solar M, Soldatov EY, Soldevila U, Solodkov AA, Soloshenko A, Solovyanov OV, Solovyev V, Sommer P, Son H, Song HY, Sood A, Sopczak A, Sopko V, Sorin V, Sosa D, Sotiropoulou CL, Soualah R, Soukharev AM, South D, Sowden BC, Spagnolo S, Spalla M, Spangenberg M, Spanò F, Sperlich D, Spettel F, Spighi R, Spigo G, Spiller LA, Spousta M, Denis RDS, Stabile A, Stamen R, Stamm S, Stanecka E, Stanek RW, Stanescu C, Stanescu-Bellu M, Stanitzki MM, Stapnes S, Starchenko EA, Stark GH, Stark J, Staroba P, Starovoitov P, Stärz S, Staszewski R, Steinberg P, Stelzer B, Stelzer HJ, Stelzer-Chilton O, Stenzel H, Stewart GA, Stillings JA, Stockton MC, Stoebe M, Stoicea G, Stolte P, Stonjek S, Stradling AR, Straessner A, Stramaglia ME, Strandberg J, Strandberg S, Strandlie A, Strauss M, Strizenec P, Ströhmer R, Strom DM, Stroynowski R, Strubig A, Stucci SA, Stugu B, Styles NA, Su D, Su J, Subramaniam R, Suchek S, Sugaya Y, Suk M, Sulin VV, Sultansoy S, Sumida T, Sun S, Sun X, Sundermann JE, Suruliz K, Susinno G, Sutton MR, Suzuki S, Svatos M, Swiatlowski M, Sykora I, Sykora T, Ta D, Taccini C, Tackmann K, Taenzer J, Taffard A, Tafirout R, Taiblum N, Takai H, Takashima R, Takeshita T, Takubo Y, Talby M, Talyshev AA, Tan KG, Tanaka J, Tanaka R, Tanaka S, Tannenwald BB, Araya ST, Tapprogge S, Tarem S, Tartarelli GF, Tas P, Tasevsky M, Tashiro T, Tassi E, Tavares Delgado A, Tayalati Y, Taylor AC, Taylor GN, Taylor PTE, Taylor W, Teischinger FA, Teixeira-Dias P, Temming KK, Temple D, Ten Kate H, Teng PK, Teoh JJ, Tepel F, Terada S, Terashi K, Terron J, Terzo S, Testa M, Teuscher RJ, Theveneaux-Pelzer T, Thomas JP, Thomas-Wilsker J, Thompson EN, Thompson PD, Thompson AS, Thomsen LA, Thomson E, Thomson M, Tibbetts MJ, Ticse Torres RE, Tikhomirov VO, Tikhonov YA, Timoshenko S, Tipton P, Tisserant S, Todome K, Todorov T, Todorova-Nova S, Tojo J, Tokár S, Tokushuku K, Tolley E, Tomlinson L, Tomoto M, Tompkins L, Toms K, Tong B, Torrence E, Torres H, Torró Pastor E, Toth J, Touchard F, Tovey DR, Trefzger T, Tricoli A, Trigger IM, Trincaz-Duvoid S, Tripiana MF, Trischuk W, Trocmé B, Trofymov A, Troncon C, Trottier-McDonald M, Trovatelli M, Truong L, Trzebinski M, Trzupek A, Tseng JCL, Tsiareshka PV, Tsipolitis G, Tsirintanis N, Tsiskaridze S, Tsiskaridze V, Tskhadadze EG, Tsui KM, Tsukerman II, Tsulaia V, Tsuno S, Tsybychev D, Tudorache A, Tudorache V, Tuna AN, Tupputi SA, Turchikhin S, Turecek D, Turgeman D, Turra R, Turvey AJ, Tuts PM, Tyndel M, Ucchielli G, Ueda I, Ughetto M, Ukegawa F, Unal G, Undrus A, Unel G, Ungaro FC, Unno Y, Unverdorben C, Urban J, Urquijo P, Urrejola P, Usai G, Usanova A, Vacavant L, Vacek V, Vachon B, Valderanis C, Valdes Santurio E, Valencic N, Valentinetti S, Valero A, Valery L, Valkar S, Vallecorsa S, Valls Ferrer JA, Van Den Wollenberg W, Van Der Deijl PC, van der Geer R, van der Graaf H, van Eldik N, van Gemmeren P, Van Nieuwkoop J, van Vulpen I, van Woerden MC, Vanadia M, Vandelli W, Vanguri R, Vaniachine A, Vankov P, Vardanyan G, Vari R, Varnes EW, Varol T, Varouchas D, Vartapetian A, Varvell KE, Vasquez JG, Vazeille F, Vazquez Schroeder T, Veatch J, Veloce LM, Veloso F, Veneziano S, Ventura A, Venturi M, Venturi N, Venturini A, Vercesi V, Verducci M, Verkerke W, Vermeulen JC, Vest A, Vetterli MC, Viazlo O, Vichou I, Vickey T, Vickey Boeriu OE, Viehhauser GHA, Viel S, Vigani L, Vigne R, Villa M, Villaplana Perez M, Vilucchi E, Vincter MG, Vinogradov VB, Vittori C, Vivarelli I, Vlachos S, Vlasak M, Vogel M, Vokac P, Volpi G, Volpi M, von der Schmitt H, von Toerne E, Vorobel V, Vorobev K, Vos M, Voss R, Vossebeld JH, Vranjes N, Vranjes Milosavljevic M, Vrba V, Vreeswijk M, Vuillermet R, Vukotic I, Vykydal Z, Wagner P, Wagner W, Wahlberg H, Wahrmund S, Wakabayashi J, Walder J, Walker R, Walkowiak W, Wallangen V, Wang C, Wang C, Wang F, Wang H, Wang H, Wang J, Wang J, Wang K, Wang R, Wang SM, Wang T, Wang T, Wang W, Wang X, Wanotayaroj C, Warburton A, Ward CP, Wardrope DR, Washbrook A, Watkins PM, Watson AT, Watson MF, Watts G, Watts S, Waugh BM, Webb S, Weber MS, Weber SW, Webster JS, Weidberg AR, Weinert B, Weingarten J, Weiser C, Weits H, Wells PS, Wenaus T, Wengler T, Wenig S, Wermes N, Werner M, Werner MD, Werner P, Wessels M, Wetter J, Whalen K, Whallon NL, Wharton AM, White A, White MJ, White R, Whiteson D, Wickens FJ, Wiedenmann W, Wielers M, Wienemann P, Wiglesworth C, Wiik-Fuchs LAM, Wildauer A, Wilk F, Wilkens HG, Williams HH, Williams S, Willis C, Willocq S, Wilson JA, Wingerter-Seez I, Winklmeier F, Winston OJ, Winter BT, Wittgen M, Wittkowski J, Wolter MW, Wolters H, Worm SD, Wosiek BK, Wotschack J, Woudstra MJ, Wozniak KW, Wu M, Wu M, Wu SL, Wu X, Wu Y, Wyatt TR, Wynne BM, Xella S, Xu D, Xu L, Yabsley B, Yacoob S, Yakabe R, Yamaguchi D, Yamaguchi Y, Yamamoto A, Yamamoto S, Yamanaka T, Yamauchi K, Yamazaki Y, Yan Z, Yang H, Yang H, Yang Y, Yang Z, Yao WM, Yap YC, Yasu Y, Yatsenko E, Wong KHY, Ye J, Ye S, Yeletskikh I, Yen AL, Yildirim E, Yorita K, Yoshida R, Yoshihara K, Young C, Young CJS, Youssef S, Yu DR, Yu J, Yu JM, Yu J, Yuan L, Yuen SPY, Yusuff I, Zabinski B, Zaidan R, Zaitsev AM, Zakharchuk N, Zalieckas J, Zaman A, Zambito S, Zanello L, Zanzi D, Zeitnitz C, Zeman M, Zemla A, Zeng JC, Zeng Q, Zengel K, Zenin O, Ženiš T, Zerwas D, Zhang D, Zhang F, Zhang G, Zhang H, Zhang J, Zhang L, Zhang R, Zhang R, Zhang X, Zhang Z, Zhao X, Zhao Y, Zhao Z, Zhemchugov A, Zhong J, Zhou B, Zhou C, Zhou L, Zhou L, Zhou M, Zhou N, Zhu CG, Zhu H, Zhu J, Zhu Y, Zhuang X, Zhukov K, Zibell A, Zieminska D, Zimine NI, Zimmermann C, Zimmermann S, Zinonos Z, Zinser M, Ziolkowski M, Živković L, Zobernig G, Zoccoli A, zur Nedden M, Zwalinski L. Measurement of the [Formula: see text] and [Formula: see text] production cross sections in multilepton final states using 3.2 fb[Formula: see text] of [Formula: see text] collisions at [Formula: see text] = 13 TeV with the ATLAS detector

A measurement of the [Formula: see text] and [Formula: see text] production cross sections in final states with either two same-charge muons, or three or four leptons (electrons or muons) is presented. The analysis uses a data sample of proton-proton collisions at [Formula: see text] TeV recorded with the ATLAS detector at the Large Hadron Collider in 2015, corresponding to a total integrated luminosity of 3.2 fb[Formula: see text]. The inclusive cross sections are extracted using likelihood fits to signal and control regions, resulting in [Formula: see text] pb and [Formula: see text] pb, in agreement with the Standard Model predictions.

Crosstalk-free dual-view liquid crystal display using patterned E-type polarizer

We present a dual-view liquid crystal display that allows two faces of the display to be viewed in opposite directions to show different image/video content simultaneously. This device is characterized by a two-domain twisted nematic liquid crystal and a patterned E-type polarizer. Its key optical performance, including the voltage-luminance curve, crosstalk, and viewing angle, has been investigated. When observed at the best viewing angle, the crosstalk between the right and left views is less than 0.07% for all grayscales. In addition, this type of crosstalk can be immune to the misalignment between the polarizers and the liquid crystal layer. For each right/left view, the range of the viewing angle spans roughly 50°.

A measurement of the calorimeter response to single hadrons and determination of the jet energy scale uncertainty using LHC Run-1 pp-collision data with the ATLAS detector

A measurement of the calorimeter response to isolated charged hadrons in the ATLAS detector at the LHC is presented. This measurement is performed with 3.2 nb[Formula: see text] of proton-proton collision data at [Formula: see text] [Formula: see text] from 2010 and 0.1 nb[Formula: see text] of data at [Formula: see text] [Formula: see text] from 2012. A number of aspects of the calorimeter response to isolated hadrons are explored. After accounting for energy deposited by neutral particles, there is a 5% discrepancy in the modelling, using various sets of Geant4 hadronic physics models, of the calorimeter response to isolated charged hadrons in the central calorimeter region. The description of the response to anti-protons at low momenta is found to be improved with respect to previous analyses. The electromagnetic and hadronic calorimeters are also examined separately, and the detector simulation is found to describe the response in the hadronic calorimeter well. The jet energy scale uncertainty and correlations in scale between jets of different momenta and pseudorapidity are derived based on these studies. The uncertainty is 2-5% for jets with transverse momenta above 2 [Formula: see text], where this method provides the jet energy scale uncertainty for ATLAS.